Q4 2023 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2024-02-14 · accession 0000950123-24-002504
$123.4M
Reported value
14
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 52886X107 | LXEO | Lexeo Therapeutics | $29.0M | 23.5% | 2,157,623 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $25.3M | 20.5% | 3,001,319 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $22.8M | 18.4% | 15,072,340 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $10.4M | 8.46% | 1,131,175 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding | $8.9M | 7.25% | 309,846 | Common | SOLE |
| 85209E109 | — | Spruce Biosciences | $6.3M | 5.13% | 2,161,022 | Common | SOLE |
| 50107A104 | KRON1USD | Kronos Bio | $4.8M | 3.87% | 3,818,283 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $4.4M | 3.59% | 2,249,123 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.4M | 2.79% | 843,750 | Common | SOLE |
| 88369M101 | — | Theseus Pharmaceuticals | $2.9M | 2.33% | 711,479 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $2.7M | 2.17% | 1,788,160 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $2.0M | 1.59% | 251,270 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $403,815 | 0.33% | 475,077 | Common | SOLE |
| 81726A100 | — | Senti Biosciences, Inc. | $129,223 | 0.10% | 195,792 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.